CDSCO panel Approves AstraZeneca's Protocol Amendment proposal for Datopotamab Deruxtecan study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-11-07 12:45 GMT | Update On 2024-11-07 12:45 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's protocol amendment proposal to study anticancer drug Datopotamab Deruxtecan (DATODXT, DS-106)

This came after the firm presented protocol amendment 3.0 version 4.0 dated 30 July 2024, protocol no. D926PC00001. This is a study of Dato-DXd Versus the Investigator's choice chemotherapy in Patients with Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Dato-DXd is a combination of a humanized anti-TROP2 antibody and a topoisomerase I inhibitor payload. The antibody binds to TROP2, a protein that's overexpressed in tumors and associated with increased aggressiveness and metastasis. The payload is then released, which targets DNA topoisomerase I and inhibits DNA replication, resulting in tumor cell death.

Dato-DXd is being studied in clinical trials for multiple cancers, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and HR-positive, HER2-negative breast cancer.

At the recent SEC meeting for Oncology held on 23rd October 2024, the expert panel reviewed the protocol amendment 3.0 version 4.0 dated 30 July 2024 protocol no. D926PC00001.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read: CDSCO panel approves Sanofi Healthcare's protocol amendment proposal to study SAR441566

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO panel Approves AstraZeneca's Protocol Amendment proposal for Datopotamab Deruxtecan study

Similar News

Sanofi gets USFDA fast track designation for neovascular age-related macular degeneration gene therapy

Braille Labels, QR Code Voice Assistance on Drugs? CDSCO Seeks Stakeholder Comments

Tata Elxsi inaugrates Bayer Development Centre in Radiology at Pune

NPPA Notifies Ceiling Prices for IV Fluids in Advanced Packaging Formats, Details

AstraZeneca Gets SEC Approval to Conduct Phase IV Trial of Hyperkalemia Drug Sodium Zirconium Cyclosilicate

CDSCO Panel Flags Inadequate Data, Withholds Pilot Study Nod for BPH Pulse Field Ablation Device

Shukra Pharma wins rights to distribute Wockhardt advanced anti-infective formulations across India

Biocon inaugurates first US manufacturing facility in New Jersey